Nutlin-3

Catalog No.S1061

Nutlin-3 Chemical Structure

Molecular Weight(MW): 581.5

Nutlin-3 is a potent and selective Mdm2 (RING finger-dependent ubiquitin protein ligase for itself and p53) antagonist with IC50 of 90 nM in a cell-free assay; stabilizes p73 in p53-deficient cells.

Size Price Stock Quantity  
In DMSO USD 185 In stock
USD 110 In stock
USD 170 In stock
USD 370 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  •  

    p53 activation in A76T p53-mutated UKF-NB-3’RITA(10 uM) IV cells. Cells were treated with RITA (10 uM) or nutlin-3 (10 uM) for 24 h and investigated by western blot for the expression of p53 target genes

    Cell death dis 2012 3, e294. Nutlin-3 purchased from Selleck.

    Caspase 3/7 activation in UKF-NB-3 or UKF-NB-3rNutlin10 μM cells treated nutlin-3 (10 μM), VCR (10 ng/ml), DOX (20 ng/ml), or CDDP (1000 ng/ml).

    Cell Death Dis 2011 2, e243. Nutlin-3 purchased from Selleck.

  • Ubiquitination of p53 in vivo by BIRC6 in the presence of Nutlin-3. Cells were treated with Nutlin-3 (20 uM, 24 h) before harvest. Cell lysates were immunoprecipitated with anti-p53 antibody and immunoblotted by anti-ubiquitin antibody.

    Int J Oncol 2014 44, 761-8. Nutlin-3 purchased from Selleck.

    d qPCR evaluation of DKK1 in MSCs exposed to melphalan in combination with increasing concentrations of nutlin-3 for 24 h. Cells were pre-treated with nutlin-3 for 20 min prior to chemotherapy. *Indicates p value<0.05, One-way ANOVA with Holm-Sidak post hoc

    Med Oncol, 2016, 33(10):113. Nutlin-3 purchased from Selleck.

Purity & Quality Control

Choose Selective Mdm2 Inhibitors

Biological Activity

Description Nutlin-3 is a potent and selective Mdm2 (RING finger-dependent ubiquitin protein ligase for itself and p53) antagonist with IC50 of 90 nM in a cell-free assay; stabilizes p73 in p53-deficient cells.
Targets
Mdm2 [5]
(Cell-free assay)
180 nM
In vitro

Nutlin-3 potently inhibits the MDM2-p53 interaction, leading to the activation of the p53 pathway. Nutlin-3 treatment induces the expression of MDM2 and p21, and displays potent antiproliferative activity with IC50 of ~1.5 μM, only in cells with wild-type p53 such as HCT116, RKO and SJSA-1, but not in the mutant p53 cell lines SW480 and MDA-MB-435. In SJSA-1 cells, Nutlin-3 treatment at 10 μM for 48 hours significantly induces caspase-dependent cell apoptosis by ~45%. Although Nutlin-3 also inhibits the growth and viability of human skin (1043SK) and mouse embryo (NIH/3T3) with IC50 of 2.2 μM and 1.3 μM, respectively, cells remain viable 1 week post-treatment even at 10 μM of Nutlin-3, in contrast with the SJSA-1 cells with viability lost at 3 μM of Nutlin-3 treatment. [1] Nutlin-3 does not induce the phosphorylation of p53 on key serine residues and reveals no difference in their sequence-specific DNA binding and ability to transactivate p53 target genes compared with phosphorylated p53 induced by the genotoxic drugs doxorubicin and etoposide, demonstrating that phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. [2] Although binding less efficiently to MDMX than to MDM2, Nutlin-3 can block the MDMX–p53 interaction and induce the p53 pathway in retinoblastoma cells (Weri1) with IC50 of 0.7 μM. [3] Nutlin-3 at 30 μM also disrupts endogenous p73-HDM2 interaction and enhances the stability and proapoptotic activities of p73, leading to the dose-dependent cell growth inhibition and apoptosis induction in cells without wild-type p53. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF7 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPX[pA2yqEQvF2= NIrpWmI1QMLiaB?= NVTxfm9n[myxY3vzJFI4NU:KQz3pcoR2[2WmIHPlcIwheHKxbHnm[ZJifGmxbjDjc41x[XKjYnzlJJRwKHSqYYSgc4Yh[mG|YXygcIV3\Wy| MVSyOlM2ODV4NR?=
NP69 NUjSfGRZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofnTWM2OD1|MT62PeKyOi53NDFOwG0> Mmi1NlYzPTJ3N{W=
NP460 NWe3flZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTJ{Lki1xtEyNjF6IN88US=> Mn\SNlYzPTJ3N{W=
C666-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTF7Lkm1xtE5Njl|IN88US=> MlriNlYzPTJ3N{W=
C666-1 MWHD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NUi3O49QOTBiwsXN Mmn1OFghcA>? MVTEUXNQ Mnnhd4Vve2m2aYrld{BEPjZ4LUGgZ4VtdHNidH:geIhmKGO7dH;0c5hq[yCnZn\lZ5Qhd2ZiY3nzdIxifGmw MV[yOlI2OjV5NR?=
C666-1  M4P0XGZ2dmO2aX;uJGF{e2G7 MorGNVAhyrWP MWWyOEBp NULYeVQ5TE2VTx?= MnnIZYN1cX[jdHXzJJRp\SCyNUOgdIF1cHejeTygeZBz\We3bHH0bY5oKHB3MzygdFIyKGGwZDDN[I0z NFXIRZAzPjJ3MkW3OS=>
C666-1 MV\BdI9xfG:|aYOgRZN{[Xl? MXexNEDDvU1? NUHKbpR{PDhxN{KgbC=> NH7QSohFVVOR NVXWe|I6e2Wwc3n0bZpmeyCFNk[2MVEh[2WubIOgeI8h[2m|cHzheIlvNWmwZIXj[YQh[XCxcITvd4l{ MUOyOlI2OjV5NR?=
A549 NE\oTVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH33T5ozPCCq NXzibnRYUUN3ME2xO{43QCEEsTC0MlUzKM7:TR?= MUOyOlEzPTJ|MB?=
A549-NTC NHnaZYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33OZ|I1KGh? MmHQTWM2OD1zOT60NkDDuSBzLkm2JO69VQ>? M4TjclI3OTJ3MkOw
A549-920 M{j2Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUe4foZROjRiaB?= MoPJTWM2OD1|Mz64OUDDuSB2Lki0JO69VQ>? Ml3HNlYyOjV{M{C=
CRL-5908 NE\NdFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUKyOEBp MXPJR|UxRTN6LkexJOKyKDJwNEOg{txO MXiyOlEzPTJ|MB?=
L6 M2nsbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfGUlUyOMLizszNxsA> MYGyOE81QC95MjDo Mn\KSG1UVw>? Ml\NbY5pcWKrdIOgZ4VtdHNicILvcIln\XKjdHnvckBidmRiZHnm[oVz\W62aXH0bY9v M2jVOFI2QDdzN{m0
C2C12 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVr2fmpbOTEEoN88UeKh NXzr[VBuOjRxNEivO|IhcA>? MYXEUXNQ NWHScHVNcW6qaXLpeJMh[2WubIOgdJJwdGmoZYLheIlwdiCjbnSg[Iln\mW{ZX70bYF1cW:w NIHmV4czPTh5MUe5OC=>
MCF-7  NVi4XIJqTnWwY4Tpc44hSXO|YYm= NF35UHgyOMLizszN NIPKNJJFVVOR MYTpcohq[mm2czDjfYNtcW5iREGgZY5lKESrY3XyxsA> NEi3W4IzPTdyMkewNy=>
DU4475  NX7KZlFmTnWwY4Tpc44hSXO|YYm= M1njVlUwOTBxMkCg{txO M{fKZVI1yqCq NETnbG9ld3ewcnXneYxifGW|IGTvZ4EuOSCmb4PlJIRmeGWwZHXueIx6 NFnuTFEzPTV2N{G3OC=>
SMMC-7721 NUPDU4JxTnWwY4Tpc44hSXO|YYm= NImzdpYyOCEQvF2= MlnvOFghcA>? M1[0T2ROW09? M3XxcYNifXOnczDEUmEhTFOEIHThcYFo\Q>? NGO5c2UzPTV2NEO2NS=>
SMMC-7721 MULGeY5kfGmxbjDBd5NigQ>? MkHKNVAh|ryP MVi0PEBp NYPPOZAxTE2VTx?= NV\3S3AzcW6mdXPld{B1cGViY3jyc41ifGmwLXLveY5lKHC{b4TlbY4hUU[LMU[geI8heGG{dHnhcIx6KGyxY3HsbZpmKGmwIITo[UBkgXSxcHzhd43DqA>? M{jEbVI2PTR2M{[x
SMMC-7721 MmrySpVv[3Srb36gRZN{[Xl? NV3G[pRPOTBizszN MXu0PEBp NGTTUWpFVVOR NGTlT2JqdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3dCpGlHVkJzwrDtVm5C NXGybm1qOjV3NESzOlE>
SMMC-7721 NX3tNHduTnWwY4Tpc44hSXO|YYm= NVvzeoNkOTBizszN MYOzOkBp NGq2c|dFVVOR NFTyNlJk[XW|ZYOgeIhmKGWldH;wbYMh\XiycnXzd4lwdiCxZjDJSmkyPg>? Ml\HNlU2PDR|NkG=
MCF-7 MWrGeY5kfGmxbjDBd5NigQ>? NX3mOmhDOTEEoN88US=> MYKwMVI1KGh? NVzDTVdVcW6mdXPld{BxPTNiYX7kJJAzOS:FaYCx NYLCd|J3OjV2OEKzO|M>
OVCAR10 NWfM[FhTTnWwY4Tpc44hSXO|YYm= NIjrbFcyOMLizszN NHvNXHMzOWkEoB?= NV7Ee5p[TE2VTx?= M4rwdolv[3KnYYPld{BxPTNicILveIVqdiCuZY\lcJM> MljBNlU1OjZ3NEi=
NCI-H23 MofwSpVv[3Srb36gRZN{[Xl? MmrXNVDDqM7:TR?= MVqyNYjDqA>? NG\HfVFFVVOR NVG5[VdicW6lcnXhd4V{KHB3MzDwdo91\WmwIHzleoVtew>? M3nzXFI2PDJ4NUS4
A2780 M1LNSGZ2dmO2aX;uJGF{e2G7 NFG2WZEyOMLizszN MXOyNYjDqA>? MXnEUXNQ Mnj6bY5kemWjc3XzJJA2OyCycn;0[YlvKGyndnXsdy=> NFe0d4szPTR{NkW0PC=>
NCI-H23 NYXoc3lTTnWwY4Tpc44hSXO|YYm= NH\3NFQyOMLizszN NI\zPJYzOWkEoB?= NYDDT5llTE2VTx?= MkHx[IVkemWjc3XzJJRp\SCIb4jNNUBt\X[nbIO= MVSyOVQzPjV2OB?=
A2780 MkfUSpVv[3Srb36gRZN{[Xl? NXX2V2ZLOTEEoN88US=> MXyyNYjDqA>? MlT3SG1UVw>? MWPk[YNz\WG|ZYOgeIhmKE[xeF2xJIxmfmWucx?= MUmyOVQzPjV2OB?=
HCT116  Mnr2SpVv[3Srb36gRZN{[Xl? MWGxNEDDvU1? Mn3QNlQhcA>? MWPjZZV{\XNiYTDwOVMu\GWyZX7k[Y51KHSndILhdIxwcWRiR{GtZZJz\XO2IHnuJIRqeGyxaXSgTGNVOTF4IHPsc45meyCGMzDhcoQhTDh? M4fwW|I2OzhyMEW1
MCF-10CA1a MUTGeY5kfGmxbjDBd5NigQ>? NF3ZbXMyOMLizszN MX[0PEBp NFzyd|RFVVOR NH[yWpVqdmirYnn0d{Bj[XOjbDDpcpZie2mxbjDhcoQhemWmdXPl[EBVT0ZvzsKzMYlv\HWlZXSgbY53[XOrb36geI8h[mG|YXygcIV3\Wy| Mne4NlUzPTd5Mkm=
MCF-10A1  M{PlTGZ2dmO2aX;uJGF{e2G7 MXixNOKh|ryP NXrsWoEyOjRxNEigbC=> MXnEUXNQ NH;1cIhqdmirYnn0d{BucWe{YYTpc44hd2Zibn;ycYFtKGK{ZXHzeEBmeGm2aHXsbYFtyqB? M{job|I2OjV5N{K5
MCF-10CA1a MkDzSpVv[3Srb36gRZN{[Xl? NVPneFBZOTEEoN88US=> MWiyOEBp NYrKbVVrTE2VTx?= NU\BO4N[\GWlcnXhd4V{KHSqZTDUS2Yu|rJ|LXnu[JVk\WRibWLORUBt\X[nbIOgc4ZOVVB{LNMgUW1RQSxiYX7kxsBqdnSnZ4LpcuKh|rMEoEO= NFz1TZAzPTJ3N{eyPS=>
MCF-10CA1a MoHkSpVv[3Srb36gRZN{[Xl? NWXyepk1OTEEoN88US=> NYHpVWxnOjRiaB?= MkjiSG1UVw>? M4jzVYlvcGmkaYTzJEBVT0ZvzsKzMYlv\HWlZXSgSXBJSjMEoH3SUmEh[W6mIIDyc5RmcW5iZYjwdoV{e2mxbh?= MnjONlUzPTd5Mkm=
SK-BR-7 MX3GeY5kfGmxbjDBd5NigQ>? NGPOO2kyOMLizszN MWmyOEBp MVXEUXNQ NHq4cJVqdmirYnn0d{AhXEeILd8yN{1qdmS3Y3XkJGVRUEJ{wrDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36= M33ZN|I2OjV5N{K5
SUM102PT M2jtOmZ2dmO2aX;uJGF{e2G7 NXO1TlhFOTEEoN88US=> NEnmUJYzPCCq M1XmNmROW09? NH;wZ2xqdmirYnn0d{AhXEeILd8yN{1qdmS3Y3XkJGVRUEJ{wrDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36= NEDFboQzPTJ3N{eyPS=>
RAW 264.7 MlH4SpVv[3Srb36gRZN{[Xl? M{TKWVExyqEQvF2= NUe2[ZNGOzBibXnu MWTwdoV3\W62czD0bIUheDV|IILl[JVkfGmxbjDpckBz\XOyb37z[UB1dyCOUGO= NXTrRWE5OjVzN{K1OFc>
RAW 264.7 NXnj[4dFTnWwY4Tpc44hSXO|YYm= NVfwe497OTEEoN88US=> NWexVWptOzBibXnu Mn;hdoVlfWOnczD0bIUhVFCVLXH1[41mdnSnZDD0bIUhVkZvzsrCJIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhZ5Rqfmm2eR?= MW[yOVE4OjV2Nx?=
RAW 264.7 M{\KW2Z2dmO2aX;uJGF{e2G7 NYPVcIlWOTEEoN88US=> NWP2ZZFPOzBibXnu NWO0NGVLcW6qaXLpeJMhVFCVLXnu[JVk\WRiTl:gdJJw\HWldHnvcuKh NX3zZlZuOjVzN{K1OFc>
MCF7  M1LydmNmdGxiVnnhZoltcXS7IFHzd4F6 MViyMlUhyrWP MljWOUBl NVnWR2o{TE2VTx?= Mo\Dd4Vve2m2aYrld{BOS0Z5IITvJHBCWlBiaX7obYJqfGmxbh?= MU[yOVA5PTlyMh?=
MCF7  NUP4SG9TTnWwY4Tpc44hSXO|YYm= MWeyMlUhyrWP MWS0PEBp MmTRSG1UVw>? MXjk[YNz\WG|ZYOgeIhmKGixbX;sc4dwfXNiRGPCJJJmeGGrcjDmdoVyfWWwY3nldy=> NHHjc2IzPTB6NUmwNi=>
ACHN M2\VfWNmdGxiVnnhZoltcXS7IFHzd4F6 NUnL[VFNOC53LUGwJO69VQ>? NIPvOJExNTZiZB?= MWHEUXNQ MnvHbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M3\yWFI2ODZ5N{i3
Caki-2 NGPnVlRE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NEj5UpYxNjVvMUCg{txO MUmwMVYh\A>? NUPmWZp3TE2VTx?= NYq4WHdzcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NETnN44zPTB4N{e4Oy=>
A498 NITHWpFE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MmryNE42NTFyIN88US=> NFfmemExNTZiZB?= NIDrUmNFVVOR MX7pcohq[mm2czDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M3PUelI2ODZ5N{i3
115 NVjKfnRQS2WubDDWbYFjcWyrdImgRZN{[Xl? NFT4RoQxNjVvMUCg{txO MoDyNE03KGR? M37LUmROW09? NHrYeFJqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NVXjV4hCOjVyNke3PFc>
117 NIjreVhE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NEnPblQxNjVvMUCg{txO M3XKO|AuPiCm MlXJSG1UVw>? M3HWeIlvcGmkaYTzJJBzd2yrZnXyZZRqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NWnZc|NoOjVyNke3PFc>
ACHN NHnvNXFHfW6ldHnvckBCe3OjeR?= NXj6WVByOC53L{GvOUDPxE1? Ml\JOFghcA>? MWXEUXNQ MkflcIVi\HNidH:gbY5kemWjc3XkJIV5eHKnc4Ppc44hd2ZicEWzJIFv\CC|b33lJJA2OyC2YYLn[ZQh\2WwZYO6JG1FVTJuIHHu[EBxOjF? NXnXcnBlOjVyNke3PFc>
Caki-2 MXPGeY5kfGmxbjDBd5NigQ>? NH\vPVExNjVxMT:1JO69VQ>? MVK0PEBp NI\lW|FFVVOR NX\ne5hLdGWjZIOgeI8hcW6lcnXhd4VlKGW6cILld5Nqd25ib3[gdFU{KGGwZDDzc41mKHB3MzD0ZZJo\XRiZ3Xu[ZM7KE2GTUKsJIFv\CCyMkG= Mn;mNlUxPjd5OEe=
A498 MlL4SpVv[3Srb36gRZN{[Xl? MUKwMlUwOS93IN88US=> M1LjUVQ5KGh? MmXqSG1UVw>? M4PkUYxm[WS|IITvJIlv[3KnYYPl[EBmgHC{ZYPzbY9vKG:oIIC1N{BidmRic3;t[UBxPTNidHHy[4V1KGenbnXzPkBOTE1{LDDhcoQheDJz MWmyOVA3Pzd6Nx?=
115 NXHKNnZFTnWwY4Tpc44hSXO|YYm= NXTqfIJUOC53L{GvOUDPxE1? NX7VPHJ[PDhiaB?= NU\4b4JnTE2VTx?= NUjK[JU5dGWjZIOgeI8hcW6lcnXhd4VlKGW6cILld5Nqd25ib3[gdFU{KGGwZDDzc41mKHB3MzD0ZZJo\XRiZ3Xu[ZM7KE2GTUKsJIFv\CCyMkG= NV\Ob4V2OjVyNke3PFc>
ACHN NGHIdHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzzPZc2KM7:TR?= MWe0PEBp MX;EUXNQ NEjrPVdqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0xsA> MXiyOVA3Pzd6Nx?=
Caki-2 NYfxbHdHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LaZ|Uh|ryP M2XWN|Q5KGh? M3LGN2ROW09? M{\SWolv\HWlZYOgZ4VtdCCleXPs[UBienKnc4VCpC=> M4rK[lI2ODZ5N{i3
A498 M1zjU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\iS|Uh|ryP M4DhR|Q5KGh? MUPEUXNQ NUHZWJRPcW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeOKh Mn3NNlUxPjd5OEe=
115 M1i4Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzQO5BQPSEQvF2= M2ntflQ5KGh? MXTEUXNQ M3e4WIlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4VCpC=> NVzWWGFmOjVyNke3PFc>
ACHN NFXnSIpHfW6ldHnvckBCe3OjeR?= MofkOUDPxE1? M3vETVQ5KGh? NEfLPGZFVVOR NF3iV2FqdmS3Y3XzJJA2Oy2mZYDlcoRmdnRic3Xu[ZNk\W6lZdMg M{fG[lI2ODZ5N{i3
Caki-2 NInJUJZHfW6ldHnvckBCe3OjeR?= NY\1R5o4PSEQvF2= NYPB[5lmPDhiaB?= NG\HUnJFVVOR NUTMWolxcW6mdXPld{BxPTNvZHXw[Y5l\W62IIPlcoV{[2WwY3ZCpC=> NEfWV2czPTB4N{e4Oy=>
A498 MonsSpVv[3Srb36gRZN{[Xl? M3flXVUh|ryP M4P6ZVQ5KGh? NI\qbphFVVOR NUXsZWNucW6mdXPld{BxPTNvZHXw[Y5l\W62IIPlcoV{[2WwY3ZCpC=> MX:yOVA3Pzd6Nx?=
115 MojnSpVv[3Srb36gRZN{[Xl? MljlOUDPxE1? MlzEOFghcA>? MnzQSG1UVw>? MVvpcoR2[2W|IIC1N{1l\XCnbnTlcpQhe2WwZYPj[Y5k\cLi Mn3GNlUxPjd5OEe=
MOLM-13 MkHjSpVv[3Srb36gRZN{[Xl? NGH5O|M3yqEQvF2= NGjEZY8xNThiaB?= MnHpSG1UVw>? MUDpcoNz\WG|ZYOgeIhmKGyndnXsd{Bw\iCyNUOsJG1FVTJuIICyNUBidmRiYXPleJlt[XSnZDDwOVM> Mkf1NlQ5QDVyOEK=
MOLM-13 MkC3SpVv[3Srb36gRZN{[Xl? NVGxNmQ3PsLizszN Mlv5OkBp NYfpclFmTE2VTx?= MVnlcohidmOnczD0bIUh[WOndInsZZRqd25ib3[gbIl{fG:wZTDINmIh[W6mIHjlZZQhe2ixY3ugdJJwfGWrboOgTJNxOjdiYX7kJGh{eDly MUmyOFg5PTB6Mh?=
HepG2 NV\TdFl4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4T2c|czKGh? M{\xN2ROW09? MYLJR|UxRTN3Lki2JOKyKDJwOTFOwG0> NVyyc2ZXOjR6OES4NFk>
HepG2/As M2nodGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVu3NkBp NX;KNVZQTE2VTx?= MXLJR|UxRTZ6LkGzJOKyKDlwNjFOwG0> MmDGNlQ5QDR6MEm=
SMMC7721 NWHEUWxMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoW4O|IhcA>? NHXKT3VFVVOR NV7v[phkUUN3ME2zNU4zQCEEsTC0MlIh|ryP M4TrcFI1QDh2OEC5
SMMC7721/Ac NUm3dYtFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjkS4c4OiCq NUDoVY9mTE2VTx?= NVTLUGZwUUN3ME21OU4zOSEEsTC1MlA{KM7:TR?= Mnm1NlQ5QDR6MEm=
Huh-7 NInncJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PzelczKGh? NFzVNm5FVVOR NXLDcnNOUUN3ME2zN{46PiEEsTCzMlkh|ryP MljrNlQ5QDR6MEm=
Hep3B MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHWO|IhcA>? M{GwNmROW09? NHjzV|hKSzVyPUKwMlE5KMLzIEGuPFQh|ryP NWXxTFFvOjR6OES4NFk>
HepG2 NEjoW3hCeG:ydH;zbZMhSXO|YYm= NGXmRYZqdmS3Y3XzJIFxd3C2b4Ppdy=> M1HtSlI1QDh2OEC5
SMMC7721 MlXvRZBweHSxc3nzJGF{e2G7 NH7UVYxqdmS3Y3XzJIFxd3C2b4Ppdy=> MmLlNlQ5QDR6MEm=
Huh-7 M132Z2Fxd3C2b4Ppd{BCe3OjeR?= MnmybY5lfWOnczDhdI9xfG:|aYO= MUWyOFg5PDhyOR?=
Hep3B MUTBdI9xfG:|aYOgRZN{[Xl? MoTPbY5lfWOnczDhdI9xfG:|aYO= NWHwUotsOjR6OES4NFk>
U2OS  NFvRN2JHfW6ldHnvckBCe3OjeR?= NWHrdYhLOjBizszN NIq4U|AzPCCq MlHCbY5kemWjc3XzJJRp\SCvUl7BJIxmfmWuczDv[uKhSkOOMlGxMEBDS0y[TNMgZY5lSkOOVx?= M3HH[|I1QDZ5MkW5
AML2 MX\BdI9xfG:|aYOgRZN{[Xl? NEDQbIQzNzFyIN88US=> NE\vbI8zPC92ODDo NHH2OZNqdmS3Y3XzJIFxd3C2b4Ppdy=> NFrKWHEzPDZ3OUe0PS=>
MOML13 M2HGdGFxd3C2b4Ppd{BCe3OjeR?= M{Dzc|IwOTBizszN NVmzemlZOjRxNEigbC=> NEeyWoJqdmS3Y3XzJIFxd3C2b4Ppdy=> M4L5RlI1PjV7N{S5
AML2 NVvSPIQxTnWwY4Tpc44hSXO|YYm= NYXlOnV{OTEQvF2= MmnYNk81KGh? MnLEbY5kemWjc3XzJJRp\SCuZY\lcEBw\iCyNUO= MXuyOFY2QTd2OR?=
AML3 MlvESpVv[3Srb36gRZN{[Xl? MUOxNO69VQ>? MV[yM|QhcA>? MkTjbY5kemWjc3XzJJRp\SCuZY\lcEBw\iCyNUO= M3vwV|I1PjV7N{S5
MOML13 MknnSpVv[3Srb36gRZN{[Xl? NVq1WmdJOTEQvF2= NVfnNGJlOi92IHi= NVPjflJicW6lcnXhd4V{KHSqZTDs[ZZmdCCxZjDwOVM> NIfaSGQzPDZ3OUe0PS=>
BeWo NWLIXlhUTnWwY4Tpc44hSXO|YYm= MkPzN|AhyrWP M13aWVI1KGh? MoTXbY5kemWjc3XzJJA2OyxiTXTtNkwheDJzIHHu[EBRfW2jIHH0JJRp\SCycn;0[YlvKGyndnXs MXmyOFQ6QDF3NB?=
BeWo MXfBdI9xfG:|aYOgRZN{[Xl? MkLWN|AhyrWP NVr1U|NZOjRiaB?= NHn5bopqdmO{ZXHz[ZMh[XCxcITvd4l{ MnW3NlQ1QThzNUS=
OCI NH7Td5JHfW6ldHnvckBCe3OjeR?= MVexNEDPxE1? NEm2OXIzPCCq MY\1dJJm\3WuYYTld{B1cGViU1;DV{0yKGW6cILld5Nqd25? M2Cwe|I1PDd|NU[y
MOLM MnLzSpVv[3Srb36gRZN{[Xl? NHj0fIoyOCEQvF2= NEDBdnEzPCCq NIK1NHl2eHKnZ4XsZZRmeyC2aHWgV29EWy1zIHX4dJJme3Orb36= NEHUWlQzPDR5M{W2Ni=>
U2OS  MUnGeY5kfGmxbjDBd5NigQ>? MUeyNEDPxE1? MmnyNlQhcA>? NXLifHRZcW6lcnXhd4V{KHSqZTDs[ZZmdHNib3[geIhmKEiRLUGgdJJwfGWrbjDhd{B4\WyuIHHzJJRp\SCyNUOgdJJwfGWrbh?= NYrSZnB[OjR|Nk[wNFc>
RKO M1nnRmZ2dmO2aX;uJGF{e2G7 M1nvPFIxKM7:TR?= NWH2T2xwOjRiaB?= MUfpcoNz\WG|ZYOgeIhmKGyndnXsd{Bw\iC2aHWgTG8uOSCycn;0[YlvKGG|IIflcIwh[XNidHjlJJA2OyCycn;0[Ylv Mn7mNlQ{PjZyMEe=
U2OS  MXrGeY5kfGmxbjDBd5NigQ>? NXHvVnJXOjBizszN NXfsV3hTOjRiaB?= MoPNbY5lfWOnczDIU{0yKGW6cILld5Nqd25iYYSgeIhmKGyndnXsJI9nKHS{YX7zZ5JqeHSrb36= M{PXRlI1OzZ4MEC3
RKO NEL4VY9HfW6ldHnvckBCe3OjeR?= MV[yNEDPxE1? MkfkNlQhcA>? MVnpcoR2[2W|IFjPMVEh\XiycnXzd4lwdiCjdDD0bIUhdGW4ZXygc4YhfHKjboPjdolxfGmxbh?= NY\USYVDOjR|Nk[wNFc>
SMMC-7721  M2\QemNmdGxiVnnhZoltcXS7IFHzd4F6 M4DTNFEvOjVvMkCg{txO MYCyOE81QC95MjDo NWeyTZpvTE2VTx?= M3\CVolvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckBld3OnIHHu[EB1cW2nIHTldIVv\GWwdHz5 MnfKNlQzQDZ|MUK=
HuH-7 NYm2TohYS2WubDDWbYFjcWyrdImgRZN{[Xl? MWOxMlI2NTJyIN88US=> NGTJS|gzPC92OD:3NkBp NGD3W5pFVVOR NYTaSHk{cW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKGSxc3WgZY5lKHSrbXWg[IVx\W6mZX70cJk> MoKxNlQzQDZ|MUK=
SMMC-7721  MWnBdI9xfG:|aYOgRZN{[Xl? NHnYV4EzOCEQvF2= NVjjXXVzPDhiaB?= MlLwSG1UVw>? MUjpcoR2[2W|IHHwc5B1d3Orcx?= MXqyOFI5PjNzMh?=
HuH-7 MXPBdI9xfG:|aYOgRZN{[Xl? MV2yNEDPxE1? M3u2UFQ5KGh? M2DhSWROW09? M1LIS4lv\HWlZYOgZZBweHSxc3nz NUXKfG42OjR{OE[zNVI>
SMMC-7721  NYPlcG9oTnWwY4Tpc44hSXO|YYm= MWqxNEDPxE1? MUmzOkBp NHv1bFVFVVOR NVzENGZ3\G:5bj3y[Yd2dGG2ZYOgeIhmKHC{b4TlbY4h\XiycnXzd4lwdiCuZY\lcEBw\iCyaH;zdIhwNVOnckO5Nk1xPTN? NVXUUFBZOjR{OE[zNVI>
HuH-7 Mn63SpVv[3Srb36gRZN{[Xl? MkH1NVAh|ryP MYSzOkBp MYXEUXNQ M2LmS4Rwf25vcnXneYxifGW|IITo[UBxem:2ZXnuJIV5eHKnc4Ppc44hdGW4ZXygc4YheGixc4Doc{1U\XJ|OUKtdFU{ NIWyT5EzPDJ6NkOxNi=>
AT2 MWHGeY5kfGmxbjDBd5NigQ>? MonLOU8yOCEQvF2= MUjs[YFleyC2bzDhJJN2[nO2YX70bYFtKGGlY4XteYxifGmxbjDv[kB1cGVicEWzJJBzd3SnaX6gZZMhf2WubDDhd{B1cGViZYjwdoV{e2mxbjDv[kBqfHNiZHny[YN1KHSjcnfleJMheDJzLDDNSG0zKGGwZDD0bIUheHKxLXHwc5B1d3SrYzDCRXgh[W6mIGDVUWEheHKxdHXpcpPDqA>? NWS1e|FqOjR{NECyNFM>
REH MmHCSpVv[3Srb36gRZN{[Xl? MWe1M|ExKM7:TR?= MmLEcIVi\HNidH:gZUB{fWK|dHHueIlidCCjY3P1cZVt[XSrb36gc4YhfGinIIC1N{Bxem:2ZXnuJIF{KHenbHygZZMhfGinIHX4dJJme3Orb36gc4YhcXS|IHTpdoVkfCC2YYLn[ZR{KHB{MTygUWROOiCjbnSgeIhmKHC{bz3hdI9xfG:2aXOgRmFZKGGwZDDQWW1CKHC{b4TlbY5{yqB? NXL5doplOjR{NECyNFM>
UoCB6 M2DCZmZ2dmO2aX;uJGF{e2G7 M{XYOlUwOTBizszN MX\s[YFleyC2bzDhJJN2[nO2YX70bYFtKGGlY4XteYxifGmxbjDv[kB1cGVicEWzJJBzd3SnaX6gZZMhf2WubDDhd{B1cGViZYjwdoV{e2mxbjDv[kBqfHNiZHny[YN1KHSjcnfleJMheDJzLDDNSG0zKGGwZDD0bIUheHKxLXHwc5B1d3SrYzDCRXgh[W6mIGDVUWEheHKxdHXpcpPDqA>? NFznWlgzPDJ2MEKwNy=>
AT2 M2PQR2NmdGxiVnnhZoltcXS7IFHzd4F6 MX:wMVI2KM7:TR?= NEnpRWpqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 NVrIfnVuOjR{NECyNFM>
REH MYnD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MojTNE0zPSEQvF2= NXzDbnhVcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= NEnhdHkzPDJ2MEKwNy=>
UoCB6 NGfROZRE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M3zXOVAuOjVizszN MkXvbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? M2S3XFI1OjRyMkCz
A2780 NYSyNYFyTnWwY4Tpc44hSXO|YYm= NGj6WJk2NzFyL{KwJO69VQ>? M4jiO|I1KGh? M3:0XpVxemWpdXzheIV{KHB3MzygUWROOixicEKxJIFv\CCGUkWgdJJwfGWrbjDs[ZZmdHNiZH;z[UBl\XCnbnTlcpRtgcLi NEDPTXAzPDF|NkG0Oy=>
H460 M{nPUmZ2dmO2aX;uJGF{e2G7 NEm3N202NzFyL{KwJO69VQ>? NGHNSVUzPCCq M4Pve5VxemWpdXzheIV{KHB3MzygUWROOixicEKxJIFv\CCGUkWgdJJwfGWrbjDs[ZZmdHNiZH;z[UBl\XCnbnTlcpRtgcLi MoKyNlQyOzZzNEe=
Lovo  NHnyc5dHfW6ldHnvckBCe3OjeR?= NYS5co9nPS9zMD:yNEDPxE1? M{jaOFI1KGh? NHLiSo52eHKnZ4XsZZRmeyCyNUOsJG1FVTJuIICyNUBidmRiRGK1JJBzd3SnaX6gcIV3\Wy|IHTvd4Uh\GWyZX7k[Y51dHoEoB?= M2TuWlI1OTN4MUS3
A2780 MkD6RZBweHSxc3nzJGF{e2G7 MVy1M|ExNzJyIN88US=> M3S2NFI1KGh? NV62RnNb\W6qYX7j[ZMh[XCxcITvd4l{KGmwZIXjeIlwdiCkeTDENlY6UC:HMUm1VkBwfmW{IILoWHJCUUx? MVOyOFE{PjF2Nx?=
H460 Mn3YRZBweHSxc3nzJGF{e2G7 NWXDSIJuPS9zMD:yNEDPxE1? MoThNlQhcA>? M1zw[4VvcGGwY3XzJIFxd3C2b4Ppd{BqdmS3Y4Tpc44h[nliREK2PWgwTTF7NWKgc5ZmeiC{aGTSRWlN M2LTUFI1OTN4MUS3
Lovo  MVnBdI9xfG:|aYOgRZN{[Xl? NG\VW2k2NzFyL{KwJO69VQ>? M1PuWlI1KGh? M{nLboVvcGGwY3XzJIFxd3C2b4Ppd{BqdmS3Y4Tpc44h[nliREK2PWgwTTF7NWKgc5ZmeiC{aGTSRWlN NFqy[XkzPDF|NkG0Oy=>

... Click to View More Cell Line Experimental Data

In vivo Oral administration of Nutlin-3 at 200 mg/kg twice daily for 3 weeks significantly inhibits the tumor growth of SJAS-1 xenografts by 90%, comparable with the effect of doxorubicin treatment with 81% inhibition of tumor growth. [1]

Protocol

Kinase Assay:

[1]

+ Expand

Biacore study:

Competition assay is performed on a Biacore S51. A Series S Sensor chip CM5 is utilized for the immobilization of a PentaHis antibody for capture of the His-tagged p53. The level of capture is ~200 response units (1 response unit corresponds to 1 pg of protein per mm2). The concentration of MDM2 protein is kept constant at 300 nM. Nutlin-3 is dissolved in DMSO at 10 mM and further diluted to make a concentration series of Nutlin-3 in each MDM2 test sample. The assay is run at 25 °C in running buffer (10 mM Hepes, 0.15 M NaCl, 2% DMSO). MDM2-p53 binding in the presence of Nutlin-3 is calculated as a percentage of binding in the absence of Nutlin-3 and IC50 is calculate
Cell Research:

[1]

+ Expand
  • Cell lines: HCT116, RKO, SJSA-1, SW480, and MDA-MB-435
  • Concentrations: Dissolved in DMSO, final concentrations ~ 30 μM
  • Incubation Time: 8, 24, and 48 hours
  • Method:

    Cells are exposed to various concentrations of Nutlin-3 for 8, 24 and 48 hours. The transcriptional levels of p21 and MDM2 genes are analyzed by real-time PCR, and protein levels by western blotting. Cell viability is measured by the MTT assay. Cell apoptosis is determined by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL) staining with flow cytometry and fluorescence microscopy.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Athymic female nude mice (Nu/Nu-nuBR) injected subcutaneously with SJSA-1 cells
  • Formulation: Formulated in 2% Klucel, 0.5% Tween 80
  • Dosages: 200 mg/kg
  • Administration: Orally, twice a day
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (171.96 mM)
Ethanol 30 mg/mL (51.59 mM)
Water Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 581.5
Formula

C30H30Cl2N4O4

CAS No. 890090-75-2
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is this a racemic mixture of Nutlin-3a and Nutlin-3b or just the Nutlin-3a enantiomer?

  • Answer:

    It is a racemate.

Mdm2 Signaling Pathway Map

Related Mdm2 Products

Tags: buy Nutlin-3 | Nutlin-3 supplier | purchase Nutlin-3 | Nutlin-3 cost | Nutlin-3 manufacturer | order Nutlin-3 | Nutlin-3 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID